Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
PAR Technology (PAR)
Consensus Price Target: $26.81 (58.7% implied return)
Originally founded in 1968 as a defense contractor for the U.S. government, PAR Technology (NYSE: PAR) provides cloud-based software, payment processing, and hardware solutions that help restaurants manage everything from point-of-sale to customer loyalty programs.
Why Does PAR Fall Short?
- Negative free cash flow raises questions about the return timeline for its investments
- Push for growth has led to negative returns on capital, signaling value destruction
PAR Technology’s stock price of $16.90 implies a valuation ratio of 22.8x forward P/E. To fully understand why you should be careful with PAR, check out our full research report (it’s free).
Ridgepost Capital (RPC)
Consensus Price Target: $13.50 (68.6% implied return)
Operating as a bridge between institutional investors and hard-to-access private market opportunities, Ridgepost Capital (NYSE: RPC) is an alternative asset management firm that provides access to private equity, venture capital, impact investing, and private credit opportunities in the middle and lower middle markets.
Why Is RPC Not Exciting?
- Performance over the past two years shows its incremental sales were less profitable, as its 6.3% annual earnings per share growth trailed its revenue gains
- Below-average return on equity indicates management struggled to find compelling investment opportunities
Ridgepost Capital is trading at $8.01 per share, or 7.2x forward P/E. Dive into our free research report to see why there are better opportunities than RPC.
One Stock to Watch:
BioMarin Pharmaceutical (BMRN)
Consensus Price Target: $87.69 (47.8% implied return)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ: BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Are We Fans of BMRN?
- Solid 14.5% annual revenue growth over the last two years indicates its offerings solve complex business issues
- Demand for the next 12 months is expected to accelerate above its two-year trend as Wall Street forecasts robust revenue growth of 28.4%
- Free cash flow margin expanded by 5.6 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $59.34 per share, BioMarin Pharmaceutical trades at 10.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
